Adrian Liston (@LabListon) header
Adrian Liston (@LabListon) profile picture

🇦🇺🇧🇪🇬🇧👨‍🔬🌈 Professor of Pathology & Head of Immunology at @Cambridge_Uni. Fellow & Welfare Tutor at @Catz_Cambridge. Founder & CSO at Aila Biotech.

Cambridge, England
Joined December 2018
Photo by Adrian Liston (@LabListon)Photo by Adrian Liston (@LabListon)Photo by Adrian Liston (@LabListon)Photo by Adrian Liston (@LabListon)Photo by Adrian Liston (@LabListon)Photo by Adrian Liston (@LabListon)Photo by Adrian Liston (@LabListon)Photo by Adrian Liston (@LabListon)Photo by Adrian Liston (@LabListon)Photo by Adrian Liston (@LabListon)
Two post-doc positions available in our lab! It is a supportive environment and one which boosts careers! Historically, of our ~30 post-docs 27% have gone on to tenure-track positions, 27% did another post-doc, and 42% have gone on to positions in biotech or pharma.
2
1
30
2,972
Adrian Liston retweeted
Replying to @francoisfleuret
I was an experimental biologist for 17 years. I'm pilled enough that I switched to scaling AI a decade ago - I've been doing nothing but scaling transformers for like 8 years. I think we'll eventually make great impacts with AI in Bio. But there's still a level of really basic delusion at play here. The timescales for testing even simple interventions in human bio is *years*. You can't iterate on a physical system faster than you can intervene. Do you have any idea how long and hard it is to recruit patients to a trial for schizophrenia or Alzheimers and how long it takes to get a readout? Same for a decent study on oncology or cardiovascular disease. There's a reason biomed people are calling this stuff out - it's Theranos-level magical thinking or borderline unethical roadshow hype.
3
6
117
4,512
I think they are counting on medical researchers and mega-rich investors being mutually-exclusive populations
1
40
It's possible to cure cancer and other diseases by literally using random chance and validating results.
7
RemindMe! 10 years not to be disappointed that bio-AI companies didn't deliver, and just sucked resources out of the system, because we would have shifted the goal posts! Remember, the important thing isn't whether diseases are cured or not, it is whether our IPO raises $$$
I don't think the interesting question is "can we cure all diseases in 10 years?" because we can't The interesting question is "10 years from now, will Bio-AI still be accelerating so quickly that failed predictions about today's tech don't matter?" Lots of people are pointing out that you pay a price for over-hyping a technology. Historically, this is true. The peak of inflated expectations is followed by the trough of disillusionment. But that model applies to a stable technology: CRISPR or RNAi, for example. These were powerful tools with a wide, but defined, scope. The CRISPR of 2026 would be recognizable to a CRISPR researcher in 2016. AI does not seem to be like that. AI accelerates. The AI tooling of 2036 won't look anything like the tooling today. It will be more powerful to a degree that is hard for me to comprehend. By the time Dario's predictions about curing all diseases are false, AI will be in effect, a new technology. There will be no time to be disappointed. I'm not sure I'm fully convinced by the above logic. But I assume some version of it is behind the choice of Dario and other neolab leaders to let rip on hype. The acceleration of AI means they don't expect to pay a price for being wrong.
1
2
842
JD Vance thinks you should have to speak English to receive care at a hospital. Wait until he hears about neonatal intensive care units. The audacity of those babies expecting care when they don’t even speak the language.
287
3,730
154
36,488
2,021,194
Those are not the labs I was praising as being elegant. This is nothing new to biology. It is just spatial transcriptomics, single cell sequencing and affymetrix wearing a trench-coat. It will get hype, more for the methodology than the insight, and the field moves on.
12
I hope, and rather predict, that elegant approaches will continue to over-perform, dollar-for-dollar, the brute-force money-bags approach. This fad is built on unrealistic hype in terms of both speed and quality, which is basically built-to-bubble.
1
11
This take is reasonable if you are from the "infinite money" class, who are limited by ideas and can simply pay other people to do anything.
1
5
53
Adrian Liston retweeted
Just got an email from a prospective PhD student containing the below. My response: I’m glad you enjoyed my work on [one short, genuine line]. It’s some of my best. As for supervising you, I think [polite refusal with an excuse - don’t mention the applicant’s AI use].
70
409
47
12,454
323,430
Wearing the R on your sleeve
Ken Paxton: The criticism has been that I let a child predator out after 1 day. Well guess what? They served 60 days.
Readers added context they thought people might want to know
Paxton's office proposed that Adam Hoffman serve 1 day in jail as part of his plea deal. The judge sentenced him to 60 days instead. He was released after serving 29 days with good behavior credit. texastribune.org/2026/05/19/ken… kwtx.com/2026/05/25/for… ibtimes.co.uk/ken-paxton-hof…
5
805
Adrian Liston retweeted
Unearthed video: Bill Clinton praises the 2007 University of Michigan senior speaker, Abdul El-Sayed, on his commencement speech "I don't want to embarrass your senior speaker. But I wish every person in the world who believes that we are fated to have a clash of civilizations and cannot reach across the religious divides could've heard you speak today. I just wish every person in the world could've heard you speak today."
286
10,941
791
86,694
5,726,237
It is only useful if it would play out again in the next panel, otherwise it is generally overfitting. We’ve all played reviewer roulette enough to know how much reviewers vary.
40
Replying to @rbdamgaard
That’s the reason. That’s always the reason.
38
Replying to @rbdamgaard
No feedback can actually be better. I find junior investigators often over-learn from comments that are essentially excuses. The real reason being “money was limiting and other applications were slightly better”. It creates a false sense that there is something to fix.
2
6
612
Adrian Liston retweeted
This Trump voter is have a REALLY tough time after the Lance Bottoms, Ossoff rally.
256
1,440
83
6,418
252,852
Adrian Liston retweeted
It's because companies coming in saying they "solved" biotech after cranking out a bunch of leads for indications like POTS and long COVID, having never dosed a patient in their lives, aren't convincing when the vast majority of drugs fail in clinic. The cash grab from generalists is obvious to subject matter experts. Maybe if the AI community had a bit more humility on the complexity of human biology, they'd get a different response.
I’ve actually been surprised by how technologically regressive and hostile the r/biotech subreddit is to machine learning. I thought Reddit would have selected against this by virtue of who has active accounts, but it is nonstop ML bashing using very out-of-date/wrong takes.
2
3
1
96
6,650
JD Vance is like the opposite of Pete Buttigieg. Back when Pete was Mayor, a doctor recalled how Pete appeared out of nowhere and served as a translator for a family in the ER:
JD Vance whines about translators in hospitals and says, "how about if everyone just spoke English?"
81
1,380
70
8,808
550,371
Replying to @AdrianoAguzzi
No, the guarantee is me copying the PMID into Endnote and checking that it is the right paper. It takes 10 seconds per paper, so it is not cost free, but that is a valuable check.
65
Replying to @AdrianoAguzzi
Personally, the 30 minutes I spent at the last stage converting PMID to Endnote references is something I'll keep as a last minute check that all the references are actually correct. It is all too easy for the wrong reference to creep into a committee document, so I check.
1
10
2,354